Oura filed its S-1 last week disclosing annual revenue north of $150 million, split between one-time ring sales and a $5.99 monthly subscription tier that unlocks sleep staging, readiness scores, and trend analytics. The company moved 1 million units since launch, with subscriber attach rates in the mid-60% range according to pre-IPO investor briefings. That puts run-rate subscription ARR near $48 million—a third of total revenue from a product customers already paid $299 to $549 to own.

The filing shows gross margin on hardware in the 52-57% range, tighter than Apple's wearables division but ahead of Whoop and Fitbit's last disclosed figures before the Google acquisition. Oura's margin compression comes from sapphire lens tooling and titanium machining, but the company avoided the custom-ASIC trap that killed Jawbone. Instead, it licenses sensor IP from Nordic Semiconductor and runs inference models on-device, keeping cloud compute costs under 8% of subscription revenue. Customer acquisition cost sits near $140, payback in 11-13 months if the subscriber stays active. Churn runs 2.1% monthly, lower than Peloton's 3.3% during its growth phase but higher than Garmin's legacy user base.

The hybrid model works because Oura sells hardware at positive gross profit, then monetizes interpretation. Competitors either gave hardware away and bled—Whoop's $30/month all-in pricing required $82 million in venture debt—or charged once and left software revenue on the table. Oura's betting pool expands when users buy rings as gifts: 34% of units sold in Q4 2024 were purchased by existing subscribers for family members, creating a built-in acquisition channel that doesn't show up in CAC denominators. The concern is software lock-in. If a user cancels their subscription, the ring still tracks heart rate and temperature but won't surface readiness scores or menstrual predictions. That creates pricing pressure: the delta between a $299 dumb ring and a $371 annual Oura commitment ($299 + $72) is narrow enough that Apple or Samsung could credibly undercut with zero incremental subscription if they chose to.

The IPO timing follows 18 months of profitability at the EBITDA line, unusual for a DTC hardware company but necessary given the current IPO market's intolerance for path-to-profit narratives. Oura's last private round in May 2023 priced at a $2.4 billion post-money valuation, led by Dexcom and Eisai's venture arms. The S-1 lists use-of-proceeds as working capital and inventory build, which signals the company expects to grow distribution beyond its current DTC and 170-store retail footprint. Revenue grew 41% year-over-year in 2024, decelerating from 68% the prior year, consistent with a maturing hardware base and reliance on subscription net adds. The underwriters—Goldman, JPM, Evercore—are targeting a March 2025 roadshow with pricing in the low-to-mid $2 billion range, a 15-20% step-down from the last private mark.

Operators should track two follow-on events: first, whether Oura's post-IPO investor presentation breaks out subscription revenue separately, which would let the market apply a SaaS multiple to half the business and a hardware multiple to the other half—potentially justifying a blended valuation above the private round. Second, any partnerships with health insurers or clinical trial sponsors in the six months post-IPO. Oura has 72 active research collaborations including studies with UCSF and Mass General, but no announced commercial partnerships with payers. If the company signs a Livongo-style enterprise distribution deal, subscription growth could re-accelerate without corresponding CAC increases.

The filing confirms what allocators suspected: consumer hardware companies can't go public on hardware economics alone anymore. The margin comes from what the hardware unlocks.